StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Softening top-line and earnings amid macro headwinds, despite strong cash flow, suggest near-term multiple compression; optionality from asset sales and India exit provides longer-term upside, but timing is uncertain.
What happened, with direct paths to the underlying reporting
FMC reported Q2 2026 revenue of $867M, with ex-India revenue of $841M, both down meaningfully year over year. The company posted a GAAP loss of $1.49 per diluted share and adjusted EBITDA of $153M, while free cash flow reached $357M, aided by a $200M upfront licensing payment for rimisoxafen. FMC outlined a plan to generate roughly $1B of debt-reduction proceeds from asset sales, including its India business sale, Newark property, and a Tessenderlo investment, as it refreshes guidance and strategy for 2026.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.